Patents by Inventor Michael David Woodrow

Michael David Woodrow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1-cyano-pyrrolidine derivatives as dub inhibitors
    Patent number: 11945797
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30).
    Type: Grant
    Filed: February 18, 2022
    Date of Patent: April 2, 2024
    Assignee: Mission Therapeutics Limited
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Michael David Woodrow
  • Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitors
    Patent number: 11414402
    Abstract: The present invention relates to a class of sulfonamide-substituted cyanopyrrolidines of Formula (Ia) and (Ib) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase L1 (UCHL1) and ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction: (Formulae (Ia), (Ib)).
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: August 16, 2022
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Martin Lee Stockley, Mark Ian Kemp, Andrew Madin, Michael David Woodrow
  • 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS
    Publication number: 20220177451
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30).
    Type: Application
    Filed: February 18, 2022
    Publication date: June 9, 2022
    Inventors: Alison JONES, Mark Ian KEMP, Martin Lee STOCKLEY, Michael David WOODROW
  • 1-cyano-pyrrolidine derivatives as DUB inhibitors
    Patent number: 11352339
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30).
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: June 7, 2022
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Michael David Woodrow
  • 4,6 dihydropyrrolo [3,4-C] pyrazole-5 (1H)-carbonitrile derivates for treating cancer
    Patent number: 11306096
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to the use of DUB or desumoylating inhibitors in the treatment of cancer. Described herein are compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c and R1d each independently represent hydrogen, optionally substituted C1-C6 alkyl or R1a and R1b together form an optionally substituted C3-C6 cycloalkyl ring, or R1c and R1d together form an optionally substituted C3-C6 cycloalkyl ring; A is a 5 membered nitrogen-containing aromatic ring and is substituted with at least one optionally substituted 5 to 10 membered monocyclic or bicyclic heteroaryl or aryl ring attached through an optional linker.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: April 19, 2022
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Michael David Woodrow
  • SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS
    Publication number: 20220106315
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of Cezanne 1. The invention further relates to the use of DUB inhibitors in the treatment of cancer.
    Type: Application
    Filed: December 14, 2021
    Publication date: April 7, 2022
    Inventors: Mark KEMP, Martin Lee STOCKLEY, Michael David WOODROW, Alison JONES
  • Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors
    Patent number: 11236092
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of Cezanne 1. The invention further relates to the use of DUB inhibitors in the treatment of cancer.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: February 1, 2022
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Mark Ian Kemp, Martin Lee Stockley, Michael David Woodrow, Alison Jones
  • 4,6 DIHYDROPYRROLO [3,4-C] PYRAZOLE-5 (1H)-CARBONITRILE DERIVATES FOR TREATING CANCER
    Publication number: 20210221813
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to the use of DUB or desumoylating inhibitors in the treatment of cancer. Described herein are compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c and R1d each independently represent hydrogen, optionally substituted C1-C6 alkyl or R1a and R1b together form an optionally substituted C3-C6 cycloalkyl ring, or R1c and R1d together form an optionally substituted C3-C6 cycloalkyl ring; A is a 5 membered nitrogen-containing aromatic ring and is substituted with at least one optionally substituted 5 to 10 membered monocyclic or bicyclic heteroaryl or aryl ring attached through an optional linker.
    Type: Application
    Filed: March 17, 2017
    Publication date: July 22, 2021
    Inventors: Alison JONES, Mark Ian KEMP, Martin Lee STOCKLEY, Michael David WOODROW
  • Cyanopyrrolidine derivatives with activity as inhibitors of USP30
    Patent number: 11014912
    Abstract: The present invention relates to substituted-cyanopyrrolidines of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: May 25, 2021
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Martin Lee Stockley, Mark Ian Kemp, Andrew Madin, Michael David Woodrow, Alison Jones
  • SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS
    Publication number: 20200247803
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of Cezanne 1. The invention further relates to the use of DUB inhibitors in the treatment of cancer.
    Type: Application
    Filed: April 8, 2020
    Publication date: August 6, 2020
    Inventors: Mark Ian KEMP, Martin Lee STOCKLEY, Michael David WOODROW, Alison JONES
  • SULFONAMIDE-SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS DUB INHIBITORS
    Publication number: 20200172518
    Abstract: The present invention relates to a class of sulfonamide-substituted cyanopyrrolidines of Formula (Ia) and (Ib) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase L1 (UCHL1) and ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction: (Formulae (Ia), (Ib)).
    Type: Application
    Filed: May 30, 2018
    Publication date: June 4, 2020
    Inventors: Martin Lee STOCKLEY, Mark Ian KEMP, Andrew MADIN, Michael David WOODROW
  • Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors
    Patent number: 10654853
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of Cezanne 1. The invention further relates to the use of DUB inhibitors in the treatment of cancer.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: May 19, 2020
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Mark Ian Kemp, Martin Lee Stockley, Michael David Woodrow, Alison Jones
  • Cyanopyrrolidine derivatives as inhibitors for DUBs
    Patent number: 10590075
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of Cezanne 1 and ubiquitin C-terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of cancer. Compounds of the invention include compounds having the formula (I): pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f and A are as defined herein.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: March 17, 2020
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Mark Ian Kemp, Michael David Woodrow
  • CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30
    Publication number: 20200017480
    Abstract: The present invention relates to substituted-cyanopyrrolidines of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 16, 2020
    Inventors: Martin Lee STOCKLEY, Mark Ian KEMP, Andrew MADIN, Michael David WOODROW, Alison JONES
  • SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS
    Publication number: 20190048008
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of Cezanne 1. The invention further relates to the use of DUB inhibitors in the treatment of cancer.
    Type: Application
    Filed: March 2, 2017
    Publication date: February 14, 2019
    Inventors: Mark Ian KEMP, Martin Lee STOCKLEY, Michael David WOODROW, Alison JONES
  • CYANOPYRROLIDINE DERIVATIVES AS INHIBITORS FOR DUBS
    Publication number: 20180362460
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of Cezanne 1 and ubiquitin C-terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of cancer. Compounds of the invention include compounds having the formula (I): pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f and A are as defined herein.
    Type: Application
    Filed: December 21, 2016
    Publication date: December 20, 2018
    Inventors: Mark Ian KEMP, Michael David WOODROW
  • Tetrahydroquinoline derivatives and their pharmaceutical use
    Patent number: 8697725
    Abstract: Tetrahydroquinoline compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: April 15, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Emmanuel Hubert Demont, Neil Stuart Garton, Romain Luc Marie Gosmini, Thomas George Christopher Hayhow, Jonathan Seal, David Matthew Wilson, Michael David Woodrow
  • Pyrazole derivatives used as CCR4 receptor antagonists
    Patent number: 8357716
    Abstract: Indazole compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: January 22, 2013
    Assignee: Glaxo Group Limited
    Inventors: Heather Hobbs, Simon Teanby Hodgson, Yannick Maurice LaCroix, Deborah Needham, Nigel James Parr, Panayiotis Alexandrou Procopiou, Timothy John Ritchie, Michael David Woodrow
  • Tetrahydroquinoline Derivatives And Their Pharmaceutical Use
    Publication number: 20120208798
    Abstract: Tetrahydroquinoline compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Application
    Filed: November 3, 2010
    Publication date: August 16, 2012
    Inventors: Emmanuel Hubert Demont, Neil Stuart Garton, Romain Luc Marie Gosmini, Thomas George Christopher Hayhow, Jonathan Seal, David Matthew Wilson, Michael David Woodrow
  • Pyrazole Derivatives Used as CCR4 Receptor Antagonists
    Publication number: 20120015932
    Abstract: Indazole compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Application
    Filed: February 24, 2010
    Publication date: January 19, 2012
    Inventors: Heather Hobbs, Simon Teanby Hodgson, Yannick Maurice LaCroix, Deborah Needham, Nigel James Parr, Panayiotis Alexandrou Procopiou, Timothy John Ritchie, Michael David Woodrow